000513 丽珠集团
已收盘 12-05 15:00:00
资讯
新帖
简况
丽珠集团（000513）披露关于回购公司股份的进展公告，12月01日股价上涨1.24%
证券之星 · 12-01
丽珠集团（000513）披露关于回购公司股份的进展公告，12月01日股价上涨1.24%
【机构调研记录】易米基金调研丽珠集团、众生药业
证券之星 · 12-01
【机构调研记录】易米基金调研丽珠集团、众生药业
每周股票复盘：丽珠集团（000513）拟变更独立董事并召开临时股东大会
证券之星 · 11-16
每周股票复盘：丽珠集团（000513）拟变更独立董事并召开临时股东大会
丽珠集团（000513）披露独立董事候选人取得独立董事培训证明，11月13日股价上涨0.19%
证券之星 · 11-13
丽珠集团（000513）披露独立董事候选人取得独立董事培训证明，11月13日股价上涨0.19%
丽珠集团（000513）披露拟取消监事会并修订公司章程，11月10日股价上涨0.29%
证券之星 · 11-10
丽珠集团（000513）披露拟取消监事会并修订公司章程，11月10日股价上涨0.29%
每周股票复盘：丽珠集团（000513）累计回购A股1537.68万股
证券之星 · 11-09
每周股票复盘：丽珠集团（000513）累计回购A股1537.68万股
丽珠集团（000513）披露回购股份进展，11月06日股价上涨0.46%
证券之星 · 11-06
丽珠集团（000513）披露回购股份进展，11月06日股价上涨0.46%
丽珠集团回购16万股 金额600万元
财中社 · 11-05
丽珠集团回购16万股 金额600万元
丽珠集团(000513.SZ)累计回购1.7%股份 耗资5.7亿元
智通财经网 · 11-03
丽珠集团(000513.SZ)累计回购1.7%股份 耗资5.7亿元
【机构调研记录】前海开源基金调研丽珠集团、神工股份等3只个股（附名单）
证券之星 · 10-28
【机构调研记录】前海开源基金调研丽珠集团、神工股份等3只个股（附名单）
每周股票复盘：丽珠集团（000513）Q3净利降5.73%
证券之星 · 10-26
每周股票复盘：丽珠集团（000513）Q3净利降5.73%
丽珠集团（000513）2025年三季报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 10-25
丽珠集团（000513）2025年三季报简析：营收净利润同比双双增长，盈利能力上升
丽珠集团公布国际专利申请：“咪唑并[1,2-a]吡啶衍生物药物组合物及其制备方法和用途”
证券之星 · 10-25
丽珠集团公布国际专利申请：“咪唑并[1,2-a]吡啶衍生物药物组合物及其制备方法和用途”
丽珠集团最新公告：前三季度净利润同比增长4.86%
证券之星 · 10-23
丽珠集团最新公告：前三季度净利润同比增长4.86%
丽珠集团（000513）披露为下属附属公司提供担保的月度进展公告，10月13日股价下跌2.1%
证券之星 · 10-13
丽珠集团（000513）披露为下属附属公司提供担保的月度进展公告，10月13日股价下跌2.1%
股市必读：丽珠集团（000513）10月10日董秘有最新回复
证券之星 · 10-13
股市必读：丽珠集团（000513）10月10日董秘有最新回复
每周股票复盘：丽珠集团（000513）A股回购1.70%股份拟注销
证券之星 · 10-12
每周股票复盘：丽珠集团（000513）A股回购1.70%股份拟注销
丽珠集团：拟收购越南上市公司Imexpharm目前经营稳健
证券之星 · 10-10
丽珠集团：拟收购越南上市公司Imexpharm目前经营稳健
丽珠集团：拥有微球流感疫苗等全球权益
证券之星 · 10-10
丽珠集团：拥有微球流感疫苗等全球权益
丽珠集团：整体业务基本盘稳固
证券之星 · 10-10
丽珠集团：整体业务基本盘稳固
加载更多
公司概况
公司名称：
丽珠医药集团股份有限公司
所属行业：
医药制造业
上市日期：
1993-10-28
主营业务：
丽珠医药集团股份有限公司的主营业务是医药产品的研发、生产及销售。公司的主要产品是消化道产品、促性激素产品、精神产品、抗感染及其他产品、原料药及中间体产品、中药制剂产品、生物制品、诊断试剂及设备产品、其他。
发行价格：
6.38
{"stockData":{"symbol":"000513","market":"SZ","secType":"STK","nameCN":"丽珠集团","latestPrice":35.78,"timestamp":1764918234000,"preClose":35.81,"halted":0,"volume":5145600,"delay":0,"changeRate":-0.0008,"floatShares":584000000,"shares":903999999,"eps":2.3698,"marketStatus":"已收盘","change":-0.03,"latestTime":"12-05 15:00:00","open":35.82,"high":35.83,"low":35.35,"amount":183000000,"amplitude":0.0134,"askPrice":35.78,"askSize":21,"bidPrice":35.77,"bidSize":443,"shortable":0,"etf":0,"ttmEps":2.3698,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":5,"adr":0,"adjPreClose":35.81,"symbolType":"stock","openAndCloseTimeList":[[1764898200000,1764905400000],[1764910800000,1764918000000]],"highLimit":39.39,"lowLimit":32.23,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":904100430,"isCdr":false,"pbRate":2.32,"roa":"--","peRate":15.098321,"roe":"12.49%","epsLYR":2.24,"committee":0.225292,"marketValue":32349000000,"turnoverRate":0.0088,"status":1,"hkstockBrief":{"symbol":"01513","market":"HK","secType":"STK","nameCN":"丽珠医药","latestPrice":31.18,"timestamp":1764922148002,"preClose":30.92,"halted":0,"volume":590055,"delay":0,"premium":"-20.85"},"floatMarketCap":20907000000},"requestUrl":"/m/hq/s/000513","defaultTab":"news","newsList":[{"id":"2588581775","title":"丽珠集团（000513）披露关于回购公司股份的进展公告，12月01日股价上涨1.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588581775","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588581775?lang=zh_cn&edition=full","pubTime":"2025-12-01 22:19","pubTimestamp":1764598783,"startTime":"0","endTime":"0","summary":"截至2025年12月1日收盘，丽珠集团报收于35.99元，较前一交易日上涨1.24%，最新总市值为325.39亿元。该股当日开盘35.51元，最高36.0元，最低35.42元，成交额达1.87亿元，换手率为0.89%。近日，丽珠集团发布关于回购公司股份的进展公告。公告显示，丽珠医药集团股份有限公司于2024年12月24日和2025年5月29日分别召开股东大会，审议通过回购部分A股股份方案及继续实施回购A股股份方案，并授予董事会回购H股的一般授权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100036608.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0187","000513","BK0028"],"gpt_icon":0},{"id":"2588874719","title":"【机构调研记录】易米基金调研丽珠集团、众生药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2588874719","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588874719?lang=zh_cn&edition=full","pubTime":"2025-12-01 08:02","pubTimestamp":1764547333,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月28日披露的机构调研信息，易米基金近期对2家上市公司进行了调研，相关名单如下：1）丽珠集团 调研纪要：LZM012银屑病适应症计划下月递交上市申请，已获CDE优先审评确认，强直适应症预计明年上半年申报。旗下最近一年表现最佳的公募基金产品为易米低碳经济股票发起A，最新单位净值为1.13，近一年增长45.15%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100000276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000513","BK0187","BK0028","BK0077","BK0188","002317"],"gpt_icon":0},{"id":"2583514906","title":"每周股票复盘：丽珠集团（000513）拟变更独立董事并召开临时股东大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2583514906","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583514906?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:52","pubTimestamp":1763236334,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，丽珠集团报收于37.6元，较上周的37.41元上涨0.51%。本周关注点公司公告汇总：丽珠集团提名王智瑶为独立董事候选人，将召开临时股东大会审议相关议案。该提名尚需提交股东大会审议，并经深圳证券交易所备案审核无异议后方可表决。近日，公司收到通知，王智瑶女士已完成线上独立董事任前培训，并取得深圳证券交易所认可的培训证明，其任职资格和独立性已通过深交所备案审核无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","000513","BK0188","BK0187"],"gpt_icon":0},{"id":"2583359919","title":"丽珠集团（000513）披露独立董事候选人取得独立董事培训证明，11月13日股价上涨0.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583359919","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583359919?lang=zh_cn&edition=full","pubTime":"2025-11-13 22:31","pubTimestamp":1763044263,"startTime":"0","endTime":"0","summary":"公司近日发布公告称，丽珠医药集团股份有限公司于2025年11月10日召开第十一届董事会第二十八次会议，提名王智瑶女士为公司独立董事候选人，该事项尚需提交股东大会审议。截至2025年第一次临时股东大会通知发出之日，王智瑶女士尚未取得独立董事培训证明，但已承诺参加最近一次任前培训。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300042429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","000513","BK0239","BK0187"],"gpt_icon":0},{"id":"2582773668","title":"丽珠集团（000513）披露拟取消监事会并修订公司章程，11月10日股价上涨0.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582773668","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582773668?lang=zh_cn&edition=full","pubTime":"2025-11-10 22:19","pubTimestamp":1762784383,"startTime":"0","endTime":"0","summary":"截至2025年11月10日收盘，丽珠集团报收于37.52元，较前一交易日上涨0.29%，最新总市值为339.22亿元。该股当日开盘37.33元，最高37.54元，最低37.07元，成交额达2.9亿元，换手率为1.33%。近日，丽珠集团发布关于召开2025年第一次临时股东大会的通知，公司将于2025年12月10日召开2025年第一次临时股东大会，会议由董事会召集，现场会议地点位于广东省珠海市金湾区创业北路38号丽珠工业园总部大楼六楼会议室。股权登记日为2025年12月3日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000034558.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","000513","BK0239","BK0187"],"gpt_icon":0},{"id":"2582869328","title":"每周股票复盘：丽珠集团（000513）累计回购A股1537.68万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2582869328","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582869328?lang=zh_cn&edition=full","pubTime":"2025-11-09 02:29","pubTimestamp":1762626549,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，丽珠集团报收于37.41元，较上周的36.74元上涨1.82%。本周关注点公司公告汇总：截至2025年10月31日，丽珠集团累计回购A股股份15,376,845股，占总股本的1.70%。公司公告汇总丽珠医药集团股份有限公司于2024年12月24日召开股东大会，审议通过回购部分A股股份方案；并于2025年5月29日审议通过继续实施回购A股方案及授予董事会回购H股一般授权。截至当日，A股已发行股份为604,293,313股，H股已发行股份为299,807,117股，库存股份为0。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900000482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","159982","BK0187","399300","BK0028","BK0239","000513"],"gpt_icon":0},{"id":"2581009463","title":"丽珠集团（000513）披露回购股份进展，11月06日股价上涨0.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581009463","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581009463?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:29","pubTimestamp":1762439355,"startTime":"0","endTime":"0","summary":"截至2025年11月6日收盘，丽珠集团报收于36.73元，较前一交易日上涨0.46%，最新总市值为332.08亿元。该股当日开盘36.58元，最高36.79元，最低36.41元，成交额达1.93亿元，换手率为0.9%。根据公司近日披露的翌日披露报表，丽珠医药集团股份有限公司于2025年11月6日在深圳证券交易所回购A股股份。本次购回的股份拟注销，未持作库存股份。截至2025年11月6日，公司已发行A股股份总数为604,293,313股。此次回购在深交所进行，符合相关上市规则及监管要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600038276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0187","BK0028","000513"],"gpt_icon":0},{"id":"2581249721","title":"丽珠集团回购16万股 金额600万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2581249721","media":"财中社","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581249721?lang=zh_cn&edition=full","pubTime":"2025-11-05 19:41","pubTimestamp":1762342860,"startTime":"0","endTime":"0","summary":"丽珠集团（000513/01513）发布公告，2025年11月5日回购16万股，支付总金额为600万元，回购价格区间为每股36.41元至36.64元。 2025年前三季度，丽珠集团实现收入91.16亿元，归母净利润17.54亿元。（文章来源：财中社）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/zqgd/2025-11-05/doc-infwkazv2846548.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000513","BK0028","BK0239","BK0187","BK0188"],"gpt_icon":0},{"id":"2580262489","title":"丽珠集团(000513.SZ)累计回购1.7%股份 耗资5.7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2580262489","media":"智通财经网","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580262489?lang=zh_cn&edition=full","pubTime":"2025-11-03 16:37","pubTimestamp":1762159075,"startTime":"0","endTime":"0","summary":"丽珠集团(000513.SZ)公告，公司截至2025年10月31日通过集中竞价交易...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/astock/8.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/8.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","BK0188","BK0187","BK0028","000513"],"gpt_icon":0},{"id":"2578084146","title":"【机构调研记录】前海开源基金调研丽珠集团、神工股份等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2578084146","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578084146?lang=zh_cn&edition=full","pubTime":"2025-10-28 08:05","pubTimestamp":1761609913,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及10月27日披露的机构调研信息，前海开源基金近期对3家上市公司进行了调研，相关名单如下：1）丽珠集团 个股亮点：公司已正式完成DeepSeek-R1 671B“满血”版的部署应用，成为国内首批将千亿参数级AI模型引入核心业务的医药企业2）神工股份 调研纪要：公司硅零部件用于存储芯片刻蚀工艺，消耗量随开工率提升而增加，受益于国产替代及海外技术限制，市场机会显现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800009002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0214","BK0188","BK0239","BK0187","688233","BK0028","000513","BK0235"],"gpt_icon":0},{"id":"2578202500","title":"每周股票复盘：丽珠集团（000513）Q3净利降5.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578202500","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578202500?lang=zh_cn&edition=full","pubTime":"2025-10-26 04:53","pubTimestamp":1761425587,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，丽珠集团报收于36.49元，较上周的37.37元下跌2.35%。本周，丽珠集团10月22日盘中最高价报37.85元。股本股东变化截至2025年9月30日，丽珠集团股东户数为4.73万户，较6月30日增加913户，增幅1.97%。业绩披露要点2025年第三季度营业收入2,844,001,646.29元，同比增长1.60%；归母净利润473,012,359.77元，同比下降5.73%；扣非归母净利润453,566,535.70元，同比下降4.58%。2025年前三季度累计营业收入9,115,914,290.40元，同比增长0.38%；归母净利润1,754,100,316.30元，同比增长4.86%；经营性现金流净额2,525,421,252.84元，同比增长9.42%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600001380.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","000513","BK0188","BK0187","BK0239"],"gpt_icon":0},{"id":"2578952541","title":"丽珠集团（000513）2025年三季报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2578952541","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578952541?lang=zh_cn&edition=full","pubTime":"2025-10-25 06:05","pubTimestamp":1761343505,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期丽珠集团发布2025年三季报。截至本报告期末，公司营业总收入91.16亿元，同比上升0.38%，归母净利润17.54亿元，同比上升4.86%。按单季度数据看，第三季度营业总收入28.44亿元，同比上升1.6%，第三季度归母净利润4.73亿元，同比下降5.73%。本报告期丽珠集团盈利能力上升，毛利率同比增幅0.87%，净利率同比增幅9.06%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102500005488.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000513"],"gpt_icon":0},{"id":"2578234715","title":"丽珠集团公布国际专利申请：“咪唑并[1,2-a]吡啶衍生物药物组合物及其制备方法和用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2578234715","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578234715?lang=zh_cn&edition=full","pubTime":"2025-10-25 05:30","pubTimestamp":1761341452,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示丽珠集团（000513）公布了一项国际专利申请，专利名为“咪唑并[1,2-a]吡啶衍生物药物组合物及其制备方法和用途”，专利申请号为PCT/CN2025/089934，国际公布日为2025年10月23日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来丽珠集团已公布的国际专利申请3个，较去年同期减少了25%。结合公司2025年中报财务数据，今年上半年公司在研发方面投入了4.32亿元，同比减11.94%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102500004989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0187","000513","BK0028"],"gpt_icon":0},{"id":"2577374606","title":"丽珠集团最新公告：前三季度净利润同比增长4.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577374606","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577374606?lang=zh_cn&edition=full","pubTime":"2025-10-23 17:20","pubTimestamp":1761211210,"startTime":"0","endTime":"0","summary":"丽珠集团(000513.SZ)公告称，丽珠集团（000513.SZ）发布2025年第三季度报告，第三季度实现营业收入28.44亿元，同比增长1.60%；归属于上市公司股东的净利润为4.73亿元，同比下降5.73%。前三季度实现营业收入91.16亿元，同比增长0.38%；归属于上市公司股东的净利润为17.54亿元，同比增长4.86%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102300026855.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000513"],"gpt_icon":0},{"id":"2575936407","title":"丽珠集团（000513）披露为下属附属公司提供担保的月度进展公告，10月13日股价下跌2.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575936407","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575936407?lang=zh_cn&edition=full","pubTime":"2025-10-13 22:14","pubTimestamp":1760364861,"startTime":"0","endTime":"0","summary":"截至2025年10月13日收盘，丽珠集团报收于38.16元，较前一交易日下跌2.1%，最新总市值为345亿元。近日，丽珠医药集团股份有限公司发布关于为下属附属公司提供担保的月度进展公告。截至2025年9月30日，公司对控股附属公司的担保余额为217,183.93万元，占最近一期经审计归属于母公司股东净资产的15.67%。公司无逾期担保，无对外担保及诉讼担保事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101300025019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0187","000513","BK0028"],"gpt_icon":0},{"id":"2575441796","title":"股市必读：丽珠集团（000513）10月10日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2575441796","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575441796?lang=zh_cn&edition=full","pubTime":"2025-10-13 04:11","pubTimestamp":1760299870,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘，丽珠集团报收于38.98元，上涨0.52%，换手率1.03%，成交量6.02万手，成交额2.35亿元。截至2025年9月30日，公司普通股股东总数为47,362户。公司公告汇总关于回购公司股份的进展公告丽珠医药集团股份有限公司于2024年12月24日召开股东大会，审议通过回购部分A股股份方案，并于2025年5月29日审议通过继续实施A股回购及授予董事会回购H股一般授权的议案。H股方面，截至2025年9月30日，在一般授权下尚未进行回购。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101300001436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000513","BK0239","BK0187","BK0188","BK0028"],"gpt_icon":0},{"id":"2574246836","title":"每周股票复盘：丽珠集团（000513）A股回购1.70%股份拟注销","url":"https://stock-news.laohu8.com/highlight/detail?id=2574246836","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574246836?lang=zh_cn&edition=full","pubTime":"2025-10-12 03:02","pubTimestamp":1760209339,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘，丽珠集团报收于38.98元，较上周的38.45元上涨1.38%。本周关注点公司公告汇总：丽珠集团截至2025年9月30日H股与A股股本无变动。公司公告汇总：公司累计回购A股15,376,845股，占总股本1.70%，拟注销减少注册资本。A股回购用于注销减少注册资本。H股方面，截至2025年9月30日，在一般授权下尚未进行回购。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101200000772.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000513","159982","BK0028","399300","BK0239","BK0187","BK0188"],"gpt_icon":0},{"id":"2574704125","title":"丽珠集团：拟收购越南上市公司Imexpharm目前经营稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=2574704125","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574704125?lang=zh_cn&edition=full","pubTime":"2025-10-10 16:39","pubTimestamp":1760085550,"startTime":"0","endTime":"0","summary":"证券之星消息，丽珠集团10月10日在投资者关系平台上答复投资者关心的问题。拟收购越南上市公司Imexpharm目前经营稳健，公司与Imexpharm产品存在较高协同性，双方已建立密切沟通并围绕未来的业务协同提前开展规划。丽珠现有产品进入越南市场销售面临的主要问题是药品注册与生产质量认证流程存在的不确定性，但公司将借助Imexpharm的成熟市场渠道和欧盟GMP认证优势，通过产品线互补与本地化运营策略，系统性地推进市场拓展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101000025149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0187","BK0028","000513"],"gpt_icon":0},{"id":"2574125532","title":"丽珠集团：拥有微球流感疫苗等全球权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2574125532","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574125532?lang=zh_cn&edition=full","pubTime":"2025-10-10 16:31","pubTimestamp":1760085070,"startTime":"0","endTime":"0","summary":"证券之星消息，丽珠集团10月10日在投资者关系平台上答复投资者关心的问题。目前公司拥有/共享微球、流感疫苗及IL-17A/F等多个新药项目的全球/海外市场权益，技术平台和临床数据具有明显优势。海外授权是公司全球化战略的重要环节，在对项目成熟度、市场潜力及合作伙伴能力综合评估后，将适时推进授权谈判。关于仿制药出海，仍需系统应对各国专利、注册与质量等壁垒，公司已积累较丰富的经验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101000024973.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000513","BK0028","BK0239","BK0187","BK0188"],"gpt_icon":0},{"id":"2574712555","title":"丽珠集团：整体业务基本盘稳固","url":"https://stock-news.laohu8.com/highlight/detail?id=2574712555","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574712555?lang=zh_cn&edition=full","pubTime":"2025-10-10 16:31","pubTimestamp":1760085069,"startTime":"0","endTime":"0","summary":"证券之星消息，丽珠集团(000513)10月10日在投资者关系平台上答复投资者关心的问题。投资者提问：为什么选择性回复问题？用什么产品来弥补亮丙瑞林微球在广东联盟采不中标的十几个亿？今年公司会不会业绩大幅下降？丽珠集团回复：尊敬的投资者，您好！当前公司整体业务基本盘稳固，发展路径清晰，能够有效支撑可持续的业绩表现，未来公司将继续加速推动研发创新和国际化布局战略，以稳健的业绩成长回报股东。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101000024970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0028","000513","BK0187"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765143138681,"stockEarnings":[{"period":"1week","weight":0.0065},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.1399},{"period":"6month","weight":0.0084},{"period":"1year","weight":-0.0188},{"period":"ytd","weight":-0.0317}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0167},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.1529},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1644}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"丽珠医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"47343人(较上一季度增加1.97%)","perCapita":"12342股","listingDate":"1993-10-28","address":"广东省珠海市金湾区创业北路38号总部大楼","registeredCapital":"90410万元","survey":" 丽珠医药集团股份有限公司的主营业务是医药产品的研发、生产及销售。公司的主要产品是消化道产品、促性激素产品、精神产品、抗感染及其他产品、原料药及中间体产品、中药制剂产品、生物制品、诊断试剂及设备产品、其他。","listedPrice":6.38},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"丽珠集团(000513)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供丽珠集团(000513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"丽珠集团,000513,丽珠集团股票,丽珠集团股票老虎,丽珠集团股票老虎国际,丽珠集团行情,丽珠集团股票行情,丽珠集团股价,丽珠集团股市,丽珠集团股票价格,丽珠集团股票交易,丽珠集团股票购买,丽珠集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"丽珠集团(000513)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供丽珠集团(000513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}